Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Follow the links below to read about each product:
Camzyos (Bristol Myers Squibb)
Enhertu (Daiichi Sankyo, AstraZeneca)
Rebyota (Ferring Pharmaceuticals)
Tzield (Provention Bio, a Sanofi company)
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.